uploads/2017/12/U.S.-Diversified-prod-1.png

Behind Valeant’s Top US Diversified Products in 3Q17

By

Updated

Wellbutrin revenue trends

In 3Q17, Valeant Pharmaceuticals’ (VRX) Wellbutrin generated revenues of $61 million, which was ~6% lower on a YoY (year-over-year) basis and 5% higher on a quarter-over-quarter basis.

Wellbutrin (bupropion) is used for the treatment of depressive disorders. Wellbutrin reported revenues of $168 million for the first nine months of 2017.

Article continues below advertisement

Isuprel revenue trends

In 3Q17, Isuprel generated revenues of $23 million, compared with $30 million in 3Q16. In 3Q17, Isuprel witnessed a 30% fall on a YoY basis.

Isuprel is used for the treatment of certain types of abnormal heartbeats, shock, and heart failure.

Xenazine revenue trends

In 3Q17, Xenazine generated revenues of $28 million, which was ~20% lower on a YoY basis and 13% lower quarter-over-quarter.

Xenazine (tetrabenazine) is used for the treatment of individuals with chorea associated with Huntington’s disease.

Article continues below advertisement

Syprine and Cuprimine revenue trends

In 3Q17, Syprine and Cuprimine reported revenues of $18 million and $20 million, respectively, compared with $26 million and $29 million in 3Q16.

Cuprimine (penicillamine) is used for the treatment of Wilson’s disease. Syprine is used for the treatment of individuals with Wilson’s disease who are not able to tolerate penicillamine.

Ativan and Migranal AG revenue trends

In 3Q17, Ativan generated revenues of $13 million, which was ~19% lower on a quarter-over-quarter basis. In 3Q17, Ativan’s YoY (year-over-year) revenues remained flat.

Ativan (lorazepam) is used for the treatment of anxiety disorders.

In 3Q17, Migranal generated revenues of $14 million, which was ~7% lower on a YoY basis and 7% lower quarter-over-quarter.

Migranal AG (dihydroergotamine mesylate) is used for acute treatment of migraine headaches with or without aura. In the marketplace, Migranal AG’s competition includes Pfizer’s (PFE) Replax, GlaxoSmithKline’s (GSK) Imitrex, and Pernix Therapeutics’ (PTX) Treximet.

Mephyton and Obagi Nu-Derm revenue trends

In 3Q17, Mephyton generated revenues of $14 million, which represents a ~7% fall on a YoY basis. Mephyton reported revenues of $40 million for the first nine months of 2017.

Mephyton is Vitamin K1 used for treatment and prevention of low levels of certain blood clotting substances.

In 3Q17, Valeant’s Obagi Nu-Derm generated revenues of $8 million, compared with $9 million in 2Q17. Obagi Nu-Derm is used for steady bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, and senile lentigines.

Notably, the Guru Index ETF (GURU) invests ~0.33% of its total portfolio holdings in Valeant Pharmaceuticals.

Advertisement

More From Market Realist